Introducing Revvity – Expanding the boundaries of human potential through science.
All products and services previously affiliated with Oxford Immunotec are now part of Revvity.

Learn More
BRAND TRANSITION RESOURCES
Contact Us

Oxford Immunotec Announces Appointment Of President – North America And Filing For FDA Approval For T-SPOT®.TB

Oxford, UK; 19th March 2007 – Oxford Immunotec Ltd, the T cell measurement company, today announces that:

  • it has appointed Jeff Schroeder as President of its North American operations
  • it has completed its PMA filings with the FDA for approval of T-SPOT.TB for the US market

Oxford Immunotec develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first regulatory approved method for directly quantifying antigen-specific T cells. T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection.

Jeff Schroeder has been appointed in order to build the sales & marketing infrastructure for the launch of T-SPOT.TB in the US market later this year. Before joining the Company he was Vice President Sales and Marketing for Cytyc Corporation, where he led the product marketing team to develop and implement the strategic plan for the ThinPrep® Pap Test and the ThinPrep Imaging System. Prior to joining Cytyc, he spent two years as VP Sales and Marketing with Cytologix Corporation and six years in senior sales positions with Abbott Laboratories, culminating in his appointment as Director Worldwide Marketing Diagnostics Division.

T-SPOT.TB will be launched following completion of the FDA’s review of the Company’s Pre Market Approval submission which was completed in January 2007. Approval will allow Oxford Immunotec to access the North American TB testing market currently estimated to be worth over $500 million.

Commenting on the above, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “We are delighted that Jeff Schroeder has agreed to join the Company as we gear up to launch T-SPOT.TB in North America later this year. His wealth of experience in the North American diagnostics space will allow Oxford Immunotec to successfully exploit the opportunity to access the world’s largest market for TB testing following FDA approval for T-SPOT.TB. Jeff will provide the necessary leadership to successfully develop the Group’s North American operations and will play a crucial role in establishing T-SPOT.TB as the new benchmark for TB screening.”